Commission Implementing Regulation (EU) 2025/1489 of 24 July 2025 amending Implementing Regulation (EU) No 540/2011 as regards the extension of the approval periods of the active substances ametoctradin, Beauveria bassiana strains ATCC 74040 and GHA, buprofezin, clodinafop, copper compounds, cyflumetofen, daminozide, flupyradifurone, Helicoverpa armigera nucleopolyhedrovirus, mandestrobin, mandipropamid, metam, pyraclostrobin, rescalure, Spodoptera littoralis nucleopolyhedrovirus, Streptomyces lydicus strain WYEC 108, Trichoderma asperellum strain T34 and Trichoderma atroviride strain I-1237

• CELEX: Implementing Regulation (EU) 2025/1489
• Articles: 3

Article 1

The Annex to Implementing Regulation (EU) No 540/2011 is amended in accordance with the Annex to this Regulation.

Article 2

This Regulation shall enter into force on the third day following that of its publication in the Official Journal of the European Union .

Schedules & Appendices

ANNEX

ANNEX

1.

Part A of the Annex to Implementing Regulation (EU) No 540/2011 is amended as follows:

(1)

in the sixth column, expiration of approval, of row 81, Pyraclostrobin, the date is replaced by ‘15 September 2026’;

(2)

in the sixth column, expiration of approval, of row 104, Daminozide, the date is replaced by ‘15 September 2026’;

(3)

in the sixth column, expiration of approval, of row 123, Clodinafop, the date is replaced by ‘31 July 2027’;

(4)

in the sixth column, expiration of approval, of row 197, Beauveria bassiana strains ATCC 74040 and GHA, the date is replaced by ‘15 September 2027’;

(5)

in the sixth column, expiration of approval, of row 320, Buprofezin, the date is replaced by ‘15 December 2026’.

2.

Part B of the Annex to Implementing Regulation (EU) No 540/2011 is amended as follows:

(1)

in the sixth column, expiration of approval, of row 22, Metam, the date is replaced by ‘15 November 2027’;

(2)

in the sixth column, expiration of approval, of row 29, Trichoderma asperellum (strain T34), the date is replaced by ‘15 October 2027’;

(3)

in the sixth column, expiration of approval, of row 31, Cyflumetofen, the date is replaced by ‘15 October 2027’;

(4)

in the sixth column, expiration of approval, of row 32, Trichoderma atroviride strain I-1237, the date is replaced by ‘15 October 2027’;

(5)

in the sixth column, expiration of approval, of row 33, Ametoctradin, the date is replaced by ‘31 May 2028’;

(6)

in the sixth column, expiration of approval, of row 34, Mandipropamid, the date is replaced by ‘30 June 2029’;

(7)

in the sixth column, expiration of approval, of row 38, Helicoverpa armigera nucleopolyhedrovirus , the date is replaced by ‘15 October 2027’;

(8)

in the sixth column, expiration of approval, of row 42, Spodoptera littoralis nucleopolyhedrovirus , the date is replaced by ‘15 October 2027’;

(9)

in the sixth column, expiration of approval, of row 79, Streptomyces lydicus strain WYEC 108, the date is replaced by ‘30 June 2029’;

(10)

in the sixth column, expiration of approval, of row 91, Flupyradifurone, the date is replaced by ‘9 June 2029’;

(11)

in the sixth column, expiration of approval, of row 92, Rescalure, the date is replaced by ‘18 May 2028’;

(12)

in the sixth column, expiration of approval, of row 93, Mandestrobin, the date is replaced by ‘9 June 2029’.

3.

In Part E of the Annex to Implementing Regulation (EU) No 540/2011, in the sixth column, expiration of approval, of row 10, Copper compounds, the date is replaced by ‘30 June 2029’.